



SPL/NSE/2012-13
August 14, 2012

National Stock Exchange of India Limited
"EXCHANGE PLAZA",
Bandra-Kurla Complex,
Bandra (E),
MUMBAI-400 051
Fax No. 022-2659 8237/38,
022-2659 8347/48

SCRIPT CODE: 532516

Sub: **COMPLIANCE OF THE LISTING AGREEMENT**


Dear Sir,

1. In compliance with Clause 41 of the Listing Agreement, please find enclosed un-audited Financial Results (Provisional) of the Company for the quarter ended June 30, 2012 which were taken on record by the Board of Directors of the Company in their meeting held on August 14, 2012 at 5.00 P.M.
2. In compliance with Clause 41 of the Listing Agreement, please find enclosed Limited Review Report on un-audited Financial Results (Provisional) of the Company for the quarter ended June 30, 2012 from the Statutory Auditors of the Company.
3. In compliance with Clause 16 of the Listing Agreement, this is to inform you that the Register of Members and Share Transfer Books of the Company shall remain closed from September 27, 2012 to September 29, 2012 for the purpose of Annual General Meeting to be held on September 29, 2012.

This is for your information and records please.

Thanking you,

Yours faithfully,
For Surya Pharmaceutical Limited


ALKA GOYAL
(Executive Director)

Encl: As above

Surya Pharmaceutical Limited

Corporate Office : SCO 164-65, Sector 9-C, Madhya Marg, Chandigarh-160 009 (INDIA)
Tel: +91 172 5005000 FAX: +91 172 5076000 Email: info@suryapharma.com ; Website: www.suryapharma.com
Regd. Office : 1596, 1st Floor, Bhagirath Palace, Chandni Chowk, Delhi - 110 006 (INDIA)



SURYA PHARMACEUTICAL LIMITED


REGD. OFFICE: 1596, 1st Floor, Bhagirath Palace, Chandni Chowk, Delhi - 110 006 (INDIA)

UNAUDITED FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER ENDED JUNE 30, 2012

Rs. In Lacs

Sr. No.	PART -I Particulars	Quarter ended			Year Ended
		30.06.2012 Unaudited	31.03.2012 Unaudited	30.06.2011 Unaudited	31.03.2012 Audited
1	Net Sales/Income from Operations(Net of Excise Duty)	3,124.46	21,193.10	40,555.00	162,294.90
	Total	3,124.46	21,193.10	40,555.00	162,294.90
2	Expenditure				
	a. (Increase)/Decrease in Stock in Trade and WIP ,FG	(2,809.52)	(6,511.12)	(3,340.00)	5,735.44
	b. Consumption of Raw Materials	6,604.58	27,704.70	34,284.00	159,715.37
	c. Purchase of Traded Goods	-	1,836.40	-	-
	d. Employees' benefits expense	415.40	796.70	1023.60	4,091.11
	e. Depreciation/Amortisation	926.30	903.60	792.40	3,461.74
	f. Other Expenditure	1,192.00	2,745.90	1725.10	8,230.74
	g. Total	6,328.76	27,476.18	34,485.10	181,234.40
3	Profit from Operations before Other Income, Finance Costs & Exceptional Items (1-2)	(3,204.30)	(6,283.08)	6069.90	(18,939.5)
4	Other Operating Income	93.85	485.30	143.40	(3,798.13)
5	Profit before Finance Costs & Exceptional Items (3+4)	(3,110.45)	(5,797.78)	6,213.30	(22,737.63)
6	Finance Costs	5,670.88	5,277.30	3180.30	16,584.84
7	Profit after Finance Costs but before Exceptional Items (5-6)	(8,781.33)	(11,075.08)	3033.00	(39,322.47)
8	Exceptional Items	-	-	-	-
9	Profit from Ordinary Activities before tax (7+8)	(8,781.33)	(11,075.08)	3,033.00	(39,322.47)
10	Tax expenses-Current Tax & Deferred Tax	-	-	606.60	12,072.46
11	Net Profit from Ordinary Activities after tax (9-10)	(8,781.33)	(11,075.08)	2,426.40	(27,250.01)
12	Extraordinary Items	-	-	-	-
13	Net Profit for the period (11-12)	(8,781.33)	(11,075.08)	2,426.40	(27,250.01)
14	Paid-up Equity Share Capital (Face Value of Rs.1/- per Share)	2,027.50	2,027.50	2,027.50	2,027.50
15	Reserves excluding Revaluation Reserves				22,720.45
16	Earnings Per Share (EPS)				
	a. Basic and diluted EPS before Extraordinary items	-4.33	-5.46	1.20	-13.44
	b. Basic and diluted EPS after Extraordinary items	-4.33	-5.46	1.20	-13.44

A	PART -II Particulars	Quarter ended			Year Ended
		30.06.2012	31.03.2012	30.06.2011	31.03.2012
	PARTICULARS OF SHAREHOLDING				



1	Public Shareholding				
	- Number of Shares	142204998	125488750	125488750	125488750
	- Percentage of Shareholding	70.14	61.89	61.89	61.89
2	Promoter and Promoter Group Shareholding:				
	a) Pledged/Encumbered				
	- No. of Shares	59378632	76094880	47369480	76094880
	- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	98.07	98.49	61.31	98.49
	- Percentage of Shares (as a % of the total share Capital of the Company)	29.29	37.53	23.36	37.53
	b) Non-Encumbered				
	- No. of Shares	1168750	1168750	29894150	1168750
	- Percentage of Shares (as a % of the total shareholding of Promoter and Promoter Group)	1.93	1.51	38.69	1.51
	- Percentage of Shares (as a % of the total share Capital of the Company)	0.58	0.58	14.74	0.58


Particulars	3 months ended 6/30/2012
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	0
Received during the quarter	2
Disposed of during the quarter	2
Remaining unresolved at the end of the quarter	0

NOTES:

- 1 The above results have been reviewed by the Audit Committee on 14.08.2012 and taken on record by the Board of Directors at its meeting held on 14.08.2012.
- 2 The above results have undergone Limited Review by the Statutory Auditors of the Company.
- 3 Provision for Deferred tax as per AS 22 will be made in the Audited Results.
- 4 The Company operates in only one segment.
- 5 Figures have been regrouped/rearranged wherever considered necessary.

Place: Chandigarh
Date: 14th August, 2012

For and on behalf of the Board of Directors
For Surya Pharmaceutical Ltd


Aka Goyal
(Executive Director)



AAD ASSOCIATES
Chartered Accountants

1595, Sector 33-D, Chandigarh
Phone : 4651765, 9779010764
Mobile No. : 9779020765
E-mail : shamsherco@yahoo.co.in


The Board of Directors
M/s. Surya Pharmaceutical Limited
New Delhi.

We have reviewed the accompanying statement of unaudited financial results of M/s. Surya Pharmaceutical Limited for the period ended **30.06.2012**. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issue by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statements of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR AAD & ASSOCIATES
CHARTERED ACCOUNTANTS



SHAMSHER SINGH

Place: Chandigarh

Dated: August 14, 2012

M. NO. 83898